We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

First-of-Its-Kind Infectious Disease Diagnostic Platform to Deliver Rapid Antibiotic Treatment Guidance

By LabMedica International staff writers
Posted on 03 May 2023
Print article
Image: Pattern’s single-cell microbiology platform could revolutionize bacterial testing (Photo courtesy of Freepix)
Image: Pattern’s single-cell microbiology platform could revolutionize bacterial testing (Photo courtesy of Freepix)

Annually, around 1.3 million lives and countless healthcare dollars are lost due to drug-resistant bacterial infections, highlighting the urgent need for faster diagnostic tools to facilitate targeted antibiotic treatment. Conventional culture-based tests may take up to four days to provide a definitive diagnosis for critically ill patients. Research indicates that patients with drug-resistant infections face a four to seven times higher risk of death if effective antibiotic treatment is delayed by even 24 hours. Now, a revolutionary phenotypic test platform for infectious diseases has the potential to quickly identify the infection-causing pathogen and offer precise guidance on the most suitable antibiotic for treatment.

Pattern Bioscience, Inc. (Austin, TX, USA), an innovator in rapid diagnosis and antibiotic susceptibility testing (AST) for bacterial infections, is pioneering the use of single-cell microbiology to rapidly diagnose drug-resistant bacterial infections and identify effective treatments. The company's unique single-cell microbiology technology represents the first culture-free, rapid phenotypic testing platform capable of delivering clinically actionable results in a timeframe that allows healthcare professionals to administer timely, life-saving treatments to patients, significantly improving outcomes.

By employing single-cell analysis of microorganisms in conjunction with machine learning, Pattern's innovative technology can produce clinically actionable information that identifies the responsible pathogen and assesses its antibiotic susceptibility within hours, as opposed to the days needed for standard culture-based tests. Pattern's proprietary single-cell analysis technology accelerates testing by directly measuring the live response of each pathogenic cell, eliminating the need for lengthy culture procedures. Phenotypic pattern recognition encompasses every resistance mechanism, whether known or unknown, existing or emerging, simple or complex, genetic, or epigenetic. Evaluating the phenotypic bacterial response to antibiotics ensures that the clinical validity of the current gold standard is upheld for rapid testing.

Traditional lab tests require days to complete, as they depend on the time-intensive growth and average response of millions of bacteria to potential antibiotic treatments. Pattern's technology, on the other hand, allows for testing directly from non-sterile specimens, improving upon the qualities that have established traditional culture as the gold standard for bacterial diagnosis. The company's first test, which has been granted US FDA Breakthrough Device Designation, targets hospitalized patients with pneumonia. In the future, Pattern's technology is expected to support a comprehensive range of other tests.

“We believe our technology will significantly impact patient outcomes and help tackle the growing challenge of antibiotic resistance,” said Nick Arab, co-founder and CEO of Pattern Bioscience.

Related Links:
Pattern Bioscience, Inc. 

Platinum Supplier
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Gold Supplier
Automated Staining Unit
RAL Stainer
Silver Supplier
LED Fluorescence Microscope

Print article


Clinical Chemistry

view channel
Image: The new assays are designed to run on the B•R•A•H•M•S KRYPTOR compact PLUS clinical chemistry analyzer (Photo courtesy of Thermo Fisher)

Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia

Preeclampsia is a life-threatening blood pressure condition that can arise during pregnancy and the postpartum phase. This severe pregnancy complication is a primary cause of maternal and fetal mortality... Read more

Molecular Diagnostics

view channel
Image: The ClarityDX Prostate test can reduce unnecessary prostate biopsies by up to 35% (Photo courtesy of Nanostics)

Innovative Blood Test to Revolutionize Prostate Cancer Detection and Reduce Invasive Biopsies

One in six men will receive a prostate cancer diagnosis during their lives. Thankfully, if caught early, prostate cancer is highly treatable. However, the existing screening process has its limitations.... Read more


view channel
Image: The latest FDA clearance has finally brought HemoScreen to its full potential as a true POC hematology analyzer (Photo courtesy of PixCell)

True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput

An innovative 5-part differential Complete Blood Count (CBC) analyzer with direct capillary sampling capability significantly simplifies blood sampling and minimizes the pre-analytical process.... Read more


view channel
Image: A new test could detect the body’s adaptive immune response to viruses (Photo courtesy of 123RF)

Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form

The adaptive immune system is an incredible defense mechanism that allows the human body to identify and mount targeted responses against specific pathogens. T-Cells, a special kind of white blood cell,... Read more


view channel
Image: The Mitotic Counting algorithm was trained on over 100,000 individual mitosis and across seven scanner models (Photo courtesy of Gestalt Diagnostics)

New AI Algorithm for Use on Eight Types of Cancer Trained on Seven Scanner Models

A new artificial intelligence (AI) algorithm for use on one of the broadest trained environments is now available for commercial or research work. Gestalt Diagnostics (Spokane, WA, USA) has released the... Read more


view channel
Image: A new electrochemical device can quickly and inexpensively identify people at greatest risk for osteoporosis (Photo courtesy of ACS Central Science, 2023)

Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop

With the global increase in life expectancy, the incidence of age-related conditions like osteoporosis is increasing. Osteoporosis, affecting around 200 million individuals worldwide, has a higher incidence... Read more


view channel
Image: AACC Middle East is a two-day conference that brings the latest in laboratory medicine to the Middle East region (Photo courtesy of ADLM)

AACC Middle East 2023 to Explore Latest Trends in Clinical Pathology and Laboratory Medicine

The AACC Middle East Conference and Exposition will be held by the Association for Diagnostics & Laboratory Medicine (ADLM - formerly AACC, Washington, DC, USA) in partnership with Life Dx (Abu Dhabi,... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.